Market Place
Sourcing Support
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
14 Nov 2024 //
BUSINESSWIRE
Japan Approves CSL And Arcturus` Updated COVID-19 Vaccine For JN.1 Strain
13 Sep 2024 //
BUSINESSWIRE
Meiji Seika Pharma Opens Boston Office For Investment Opportunities
08 Aug 2024 //
BUSINESSWIRE
Meiji Seika to supply Japan with self-amplifying mRNA Covid-19 vaccine
22 Mar 2024 //
ENDPTS
Meiji Seika Pharma Presents Positive Findings from Phase II Study of ME3183
13 Oct 2023 //
BUSINESSWIRE
Meiji Seika Pharma, Adcock Complete Construction of New Manufacturing Facility
31 May 2023 //
CONTRACT PHARMA
Adcock Ingram Completes Construction of a New Manufacturing Facility in India
31 May 2023 //
BUSINESSWIRE
Zhejiang Hengkang Meiji Pharma to enter the field of green synthetic biology
10 Jan 2023 //
PRESS RELEASE
Meiji Seika Pharma commences Phase III mRNA Covid-19 vaccine trial in Japan
14 Dec 2022 //
CLINICALTRIALSARENA
First Patient Dosed in Phase II Study of ME3183 in Plaque Psoriasis
07 Apr 2022 //
BUSINESSWIRE
Meiji Completed Phase I Studies and Moves Onto Phase II Study of ME3183
24 Aug 2021 //
BUSINESSWIRE
Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115
21 May 2021 //
BIOSPACE
Meiji Seika Pharma Sets up a New Subsidiary in the US
04 Jan 2021 //
BUSINESSWIRE
Eisai to take over manufacturing approval for Parkinson`s disease drug
07 Sep 2020 //
PHARMABIZ
Axio Biosolutions raises Rs 36 cr in Series B-1 round
09 Jan 2020 //
BUSINESS LINE
Solasia` darinaparsin Ph 2 study patient registration reached their target
19 Sep 2019 //
BUSINESSWIRE
Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development
16 Jul 2018 //
PRESS RELEASE
Newron Pharmaceuticals S.p.A. Announces Change in the Board of Directors
18 Feb 2018 //
BUSINESSWIRE
Meiji Seika Pharma to Commercialize Solasia Pharma`s Episil in Japan
08 Dec 2016 //
PHARMABIZ
Big Three Asia Pharma Markets Poised to Soar in 2015, Reports Say
17 Mar 2015 //
FIERCE PHARMA ASIA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.